Dafinchi AI

Fulgent Genetics, Inc.

FLGT

Healthcare

2w

Progress in Clinical Pipeline with FID-007 and FID-022

FID-007 progressing through Phase II trial in head and neck cancer, with 32 patients enrolled and data readout expected in 2026.
Fid-022 in early Phase I trial targeting solid tumors such as colon, pancreatic, ovarian, and bile duct cancers.
Projected clinical trial costs are approximately $30 million for FID-007 and $8 million for FID-022, with ongoing progress seen as promising for heavily pretreated patients.

Myriad Genetics, Inc.

MYGN

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA was $14.5 million, a 24% increase year-over-year, with adjusted EPS of $0.05 for the quarter.
Adjusted gross margin improved by 140 basis points to 71.5%, reflecting operational efficiencies and favorable test mix.
Average revenue per test grew 2% year-over-year, driven by favorable test mix, sales targeting, revenue cycle projects, and expanding payer coverage.
GeneSight revenue declined 12% year-over-year due to UnitedHealthcare coverage changes but volume growth rebounded to 5% in Q2.
Hereditary cancer testing revenue grew 9% year-over-year, with oncology channel volume up 14%.
Myriad Genetics reported Q2 2025 revenue of $213 million, a 5% increase year-over-year excluding impacts from UnitedHealthcare's GeneSight coverage decision and the divested European EndoPredict business.
Prenatal revenue grew 7% year-over-year despite a 7% volume decline due to order management system issues, which have since been resolved.
Prolaris revenue grew 4% year-over-year, with volume up 6% sequentially from Q1 2025.
The company recognized a noncash goodwill and intangible impairment charge of $317 million due to market capitalization decline, excluded from non-GAAP EPS.

Myriad Genetics, Inc.

MYGN

Healthcare

1w

Myriad's Strategic Shift to Cancer Care Continuum Focus

Myriad is updating its long-range strategy to focus on the Cancer Care Continuum (CCC).
The new strategy aims to drive accelerated growth and profitability through three pillars: expanding in cancer diagnostics, growing prenatal and mental health markets, and maintaining financial discipline.
The company plans to leverage its leadership in hereditary cancer testing and expand into therapy selection, genomic profiling, immuno-oncology, and MRD testing.
Partnerships, such as with PATHOMIQ for AI-enabled prostate cancer testing, will play a key role in this expansion.
Management emphasizes increased urgency, disciplined execution, and strategic partnerships to achieve growth targets.

Arcturus Therapeutics Holdings Inc.

ARCT

Healthcare

1w

Financial Performance Summary

Cash, cash equivalents, and restricted cash totaled $253.4 million as of June 30, 2025, with a cash runway extended into 2028.
General and administrative expenses decreased to $10.3 million in Q2 2025 from $12.3 million in Q2 2024, due to reduced share-based compensation and headcount.
Net loss for Q2 2025 was approximately $9.2 million or $0.34 per diluted share, improved from a net loss of $17.2 million or $0.64 per diluted share in Q2 2024.
Research and development expenses decreased to $29.6 million in Q2 2025 from $58.7 million in Q2 2024, reflecting lower manufacturing and clinical costs for COVID, flu, and OTC programs, partially offset by higher clinical costs for cystic fibrosis.
Revenue for Q2 2025 was $28 million, down $22 million year-over-year, primarily due to lower revenues from the CSL collaboration and amortization of upfront payments as CoStave progresses toward commercialization.
Total operating expenses for Q2 2025 were $40 million, down from $71 million in Q2 2024, driven by reduced manufacturing costs, clinical trial expenses, payroll, and employee benefits.

Vir Biotechnology, Inc.

VIR

Healthcare

1w

Financial Performance Summary

Cash, cash equivalents, and investments totaled approximately $892 million at quarter-end, providing runway into mid-2027.
Net cash consumed in Q2 2025 was approximately $127.7 million, including $50.5 million in milestone payments related to ECLIPSE 1 first patient dosed; excluding milestones, net cash consumed was about $77.2 million.
Net loss for Q2 2025 was $111 million, improved from a net loss of $138.4 million in Q2 2024.
R&D expenses for Q2 2025 were $97.5 million, down from $105.1 million in Q2 2024, driven by restructuring cost savings partially offset by clinical and oncology program expenses.
SG&A expenses for Q2 2025 were $22.3 million, down from $30.3 million in Q2 2024, due to headcount reductions and restructuring.
Total operating expenses for Q2 2025 were $119.6 million, a $42.1 million decrease from Q2 2024, reflecting lower R&D, SG&A, and absence of prior restructuring charges.

AbCellera Biologics Inc.

ABCL

Healthcare

1w

Financial Performance Summary

Cash and equivalents totaled $580 million, with an additional $170 million in committed government funding, providing total available liquidity of around $750 million.
General and administrative expenses were approximately $19 million, down from $20 million, including ongoing intellectual property defense costs.
Net loss for the quarter was roughly $35 million, an improvement from a $37 million loss in Q2 2024.
Research and development expenses were about $39 million, slightly lower than the previous year by $2 million due to timing of program-specific expenses.
Revenue for Q2 2025 was approximately $17 million, up from $7 million in Q2 2024, driven by a $10 million lump sum licensing fee from the Trianni platform.
Sales and marketing expenses decreased slightly to $3 million compared to the prior year.

NovoCure Limited

NVCR

Healthcare

3w

Financial Performance Summary

Cash and investments totaled $912 million at quarter-end; $560 million in convertible notes due later this year will be retired with cash on hand.
General and administrative expenses rose 17% to $44 million, driven by higher share-based compensation and personnel costs supporting the lung cancer launch and company build-out.
Gross margin was 74%, down from 77% in Q2 2024, mainly due to rollout costs of the HFE array and non-small cell lung cancer launch prior to broad reimbursement.
Net loss was $40 million with a loss per share of $0.36; adjusted EBITDA was negative $10 million.
Net revenues were $159 million, a 6% increase from Q2 2024, driven primarily by 7% active patient growth in the GBM franchise and double-digit growth in international markets.
Research and development expenses were $56 million, up 2% year-over-year, with no expected material step-up this year due to shifting trial spend.
Sales and marketing expenses were $57 million, a 1% increase, reflecting incremental launch costs for non-small cell lung cancer mostly offset by lower stock-based compensation.
The company plans to draw $100 million from its credit facility in September as part of a four-tranche agreement, with the first two tranches obligated to be drawn.

Seres Therapeutics, Inc.

MCRB

Healthcare

1w

Financial Performance Summary

As of June 30, 2025, cash and cash equivalents stood at $45.4 million, with an expected cash runway into Q1 2026 based on current plans and obligations.
General and administrative expenses declined to $10.3 million from $13.1 million, driven by lower personnel and IT-related expenses.
Research and development expenses decreased to $12.9 million from $15.8 million year-over-year, reflecting completion of the SER-155 Phase Ib study and lower personnel and platform investment costs.
Seres Therapeutics reported a net loss from continuing operations of $19.9 million in Q2 2025, an improvement from $26.2 million in Q2 2024.
The company received a $25 million installment payment from Nestlé in July 2025.

Exact Sciences Corporation

EXAS

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA reached an all-time high of $138 million, a 26% increase, with margin expansion of 130 basis points due to pricing and productivity gains.
Cash and marketable securities ended at $858 million.
Exact Sciences delivered a record 1.3 million test results in Q2 2025, with core revenue growth accelerating to 16% year-over-year.
Free cash flow was $47 million in Q2, with year-to-date free cash flow increasing by $95 million compared to the prior year.
GAAP net income was negative $1 million, including $15 million in one-time operational efficiency costs.
Precision oncology revenue grew 9% to $179 million on a core basis, supported by Oncotype DX international adoption and sublicensing revenue from TwinStrand technology.
Screening revenue increased 18% to $628 million, driven by Cologuard rescreens, care gap programs, and improved commercial execution.

FGEN

Healthcare

1w

Financial Performance Summary

Cash and equivalents totaled $23.5 million in the U.S. and $142.1 million consolidated including China balances.
FibroGen reported total revenue of $1.3 million in Q2 2025, up from $1 million in Q2 2024.
Net loss from continuing operations was $13.7 million or $3.38 per share, improved from a $47.1 million loss or $11.79 per share in Q2 2024.
Operating costs and expenses decreased by 72% year-over-year to $13.4 million in Q2 2025.
R&D expenses fell 82% to $5.9 million, and SG&A expenses decreased 53% to $7.1 million compared to Q2 2024.
The company was cash flow positive in Q2 2025, generating $13.7 million on a consolidated basis.

FGEN

Healthcare

1w

Operational and Financial Impact of China Transaction and Cost Reductions

The sale of FibroGen China is expected to close in Q3 2025, with consideration now at approximately $210 million.
This transaction allows repayment of an $80 million senior loan, significantly reducing debt and extending cash runway.
FibroGen's cash position improved, with total cash including China balances at $142.1 million as of June 30, 2025.
Operating costs and expenses decreased by 72% year-over-year in Q2, with R&D down 82%, reflecting cost management.
The company remains cash flow positive through the transaction close, supporting ongoing U.S. development efforts.